An open, single dose, antitumor effect study of 2-hydroxyflutamide as a controlled release product (Liproca Depot), injected into the prostate in patients with localized prostate cancer.

Trial Profile

An open, single dose, antitumor effect study of 2-hydroxyflutamide as a controlled release product (Liproca Depot), injected into the prostate in patients with localized prostate cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs Hydroxyflutamide (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Sponsors LIDDS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jan 2015 Planned End Date changed from 21 Feb 2012 to 1 May 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top